Summary
The aged are now viewed as a special population for the purposes of drug development. This has produced challenges for the investigator, in that separation of age- and disease-related changes in drug effect is only beginning to be defined. In addition, development of measurement tools for use in the elderly, particularly for central nervous system-active drugs, is an important ongoing process. As investigations proceed, we can look forward to an improved understanding of the physiology of normal ageing and the impact of disease processes and drugs on this physiological functioning. For the regulatory agency, evaluation of both efficacy and toxicity data in elderly patients for a drug-in-development is required; however, at present these data will be obtained in a ‘young’ elderly group, whereas much of the clinical use of the drug will be in the ‘old’ elderly. Extrapolation from one group to the other is required, although the relevance of this extrapolation is unknown. It is reassuring that, so far, few if any drug effects or toxicities have been identified which are truly unique to the elderly, though the magnitude of pharmacological or toxicological effects may differ.
Similar content being viewed by others
References
Abernethy DR. Methodological concern for clinical trials in geriatrics: benzodiazepines. In Cutler & Narang (Eds) Drug studies in the elderly; methodologic concerns, pp. 189–205, Plenum Press, New York, 1986
Abernethy DR, Bartos P, Plachetka JR. Labetalol in the treatment of hypertension in elderly and younger patients. Journal of Clinical Pharmacology 27: 902–906, 1987
Abernethy DR, Schwartz JB, Todd EL, Luchi R, Snow E. Verapamil pharmacodynamics and disposition in young versus elderly hypertensive patients. Annals of Internal Medicine 105: 329–336, 1986
Black M, Mitchell JR, Zimmerman HJ, Ishak KJ, Epier GR. Isoniazid hepatitis in 114 patients. Gastroenterology 69: 289–302, 1973
Boston Collaborative Drug Surveillance Program. Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age. New England Journal of Medicine 288: 277–280, 1973
Greenblatt DJ, Shader RI, Abernethy DR. Current status of benzodiazepines. New England Journal of Medicine 309: 354–358 and 410–416, 1983
Messerli FH, Ventura HO, Glade LB, Sundgaard-Riise K, Dunn FG, et al. Essential hypertension in the elderly: hemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 2: 983–985, 1983
Montamat SC, Abernethy DR. Calcium antagonists in geriatric patients: diltiazem in elderly hypertensives. Clinical Pharmacology and Therapeutics 45: 682–691, 1989
Schwartz JB, Abernethy DR. Responses to intravenous and oral diltiazem in elderly versus younger patients with systemic hypertension. American Journal of Cardiology 59: 1111–1117, 1987
Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics 5: 445–479, 1977
Vestal RE, Wood AJ, Shand DG. Reduced beta-adrenoceptor sensitivity in the elderly. Clinical Pharmacology and Therapeutics 26: 181–186, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Abernethy, D.R. Research Challenges, New Drug Development, Preclinical and Clinical Trials in the Ageing Population. Drug-Safety 5 (Suppl 1), 71–74 (1990). https://doi.org/10.2165/00002018-199000051-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199000051-00011